← Back to recalls

Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

Class II
Recalling firm
Siemens Healthcare Diagnostics, Inc.
Reason for recall
The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.
Affected products (lot / model / serial)
Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers.
Units affected
24,077 units
Distribution pattern
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Oman, Pakistan, Paraguay, Poland, Portugal, Qatar, Republic of Korea, Romania, Saudi¿Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, Turkey, Turkmenistan, U.A.E., Uganda, United¿Kingdom, Uruguay, Vatican City, Vietnam.
Firm location
Tarrytown, NY, United States
Recall type
Voluntary: Firm initiated
How the firm notified customers
Letter
Product type
Devices
Status
Ongoing
Recall number
Z-2703-2026
Recall initiated
June 8, 2026
FDA classification date
July 8, 2026
FDA report date
July 15, 2026
FDA event ID
99214
Last updated on HTM Vibe
July 23, 2026
View on openFDA